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Strengths and limitations of this study
 ► Costs are estimated through an incidence- based 
approach using patient- level morbidity records.
 ► Sufficient follow- up time is used to capture all rele-
vant global costs to generate a contemporary esti-
mate of health and care home costs related to atrial 
fibrillation (AF).
 ► Scotland offers a robust record linkage system, 
where administrative patient- level health data are 
routinely collected.
 ► Data on primary care consultations were not avail-
able for linkage at a national level; however, the im-
pact this might have on overall costs is expected to 
be small.
 ► The potential risk of AF going undiagnosed and clin-
ical miscoding of morbidity records may lead to an 
underestimation of the AF cohort and associated 
costs.
AbStrACt
Objective This study aimed to estimate global inpatient, 
outpatient, prescribing and care home costs for patients 
with atrial fibrillation using population- based, individual- 
level linked data.
Design A two- part model was employed to estimate the 
probability of resource utilisation and costs conditional on 
positive utilisation using individual- level linked data.
Settings Scotland, 5 years following first hospitalisation 
for AF between 1997 and 2015.
Participants Patients hospitalised with a known diagnosis 
of AF or atrial flutter.
Primary and secondary outcome measures Inpatient, 
outpatient, prescribing and care home costs.
results The mean annual cost for a patient with AF 
was estimated at £3785 (95% CI £3767 to £3804). 
Inpatient admissions and outpatient visits accounted for 
79% and 8% of total costs, respectively; prescriptions 
and care home stay accounted for 7% and 6% of total 
costs. Inpatient cost was the main driver across all age 
groups. While inpatient cost contributions (~80%) were 
constant between 0 and 84 years, they decreased for 
patients over 85 years. This is offset by increasing care 
home cost contributions. Mean annual costs associated 
with AF increased significantly with increasing number of 
comorbidities.
Conclusion This study used a contemporary and 
representative cohort, and a comprehensive approach 
to estimate global costs associated with AF, taking into 
account resource utilisation beyond hospital care. While 
overall costs, considerably affected by comorbidity, did not 
increase with increasing age, care home costs increased 
proportionally with age. Inpatient admission was the 
main contributor to the overall financial burden of AF, 
highlighting the need for improved mechanisms of early 
diagnosis to prevent hospitalisations.
IntrODuCtIOn
Atrial fibrillation (AF) is the most common 
form of arrhythmia. In Scotland, AF affects 
1.8% of the adult population, and rises to 
6% among those aged 65 years or over.1 In 
an ageing population, AF has a substan-
tial impact on the economic burden of the 
healthcare system.
A number of cost analyses on estimating the 
economic burden of AF exist. The majority 
of these studies used various definition of the 
AF study population, based on data sourced 
from administrative database,2–4 health insur-
ance databases,2 5–7 hospital records8 9 and 
surveys.10 Direct medical costs related to 
inpatient admissions, outpatient visits, as well 
as prescriptions have been included in these 
estimates2–10; indirect costs related to loss 
of productivity have been estimated among 
patients who were at working ages.6 7
There is a lack of generalisable studies 
based on large national population datasets 
that examine the total and the distribution 
of costs associated with AF.11 The aim of this 
study was to quantify the inpatient, outpa-
tient, prescribing and care home costs asso-
ciated with AF over a 5- year period. Using 
record linkage of national datasets from Scot-
land, we also examined the distribution of 
costs that are attributable to AF.
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Table 1 Baseline characteristics of patients with AF
Characteristics N (%)
Number of patients 278 286
Mean age at first admission* (SD)** 
(range)
74* (12.5)** (0–108)
Sex   
  Male 139 928 (50.3)
  Female 138 358 (49.7)
Health boards   
  Greater Glasgow and  
Clyde
61 822 (22.2)
  Lothian 41 169 (14.8)
  Lanarkshire 31 049 (11.2)
  Grampian 25 728 (9.3)
  Ayrshire and Arran 22 003 (7.9)
  Tayside 25 003 (9.0)
  Fife 17 954 (6.5)
  Highland 18 929 (6.9)
  Forth Valley 13 664 (4.9)
  Dumfries and Galloway 9798 (3.5)
  Borders 7222 (2.6)
  Western Isles 1868 (0.7)
  Shetland 1036 (0.4)
  Orkney 1041 (0.4)
Geography   
  Large/urban 106 868 (38.4)
  Other/urban 82 601 (29.7)
  Accessible small towns 24 938 (9.0)
  Remote small towns 8272 (3.0)
  Very remote small towns 3828 (1.4)
  Accessible rural 30 826 (11.1)
  Remote rural 10 371 (3.7)
  Very remote rural 10 087 (3.6)
SIMD quintile   
  1 62 730 (22.5)
  2 62 632 (22.5)
  3 55 943 (20.1)
  4 50 691 (18.2)
  5 46 279 (16.6)
Comorbidity   
  No comorbidity 40 502 (14.6)
  1 comorbidity 53 651 (19.3)
  >1 comorbidities 184 133 (66.2)
Re- hospitalised (any condition) 179 494 (64.5)
Admitted to care home 7235 (2.6)
Mortality   
  Alive 204 690 (73.6)
  Dead 73 596 (26.4)
SIMD, Scottish Index of Multiple Deprivation.
MethODS
Cost analyses or cost of illness studies typically adopt either 
the prevalence- based or incidence- based approaches.12 In 
the context of AF, the prevalence- based approach deter-
mines costs attributable to all cases of AF in a given year, 
while the incidence- based approach determines costs of 
new cases of AF in a given time period. In the present 
study, costs were estimated with an incidence- based 
approach. A further distinction between costing analyses 
is between the medicalised and the global comprehensive 
approaches.
In the first case, only expenditures directly attributable 
to a particular disease are used for estimating the overall 
costs. While the medicalised approach can be used to 
identify highly specific expenditures, it may also lead 
to underestimation or overestimation of the economic 
burden of a given disease; this may happen when cost 
estimation is not adequately adjusted for confounders 
highly correlated with the disease of interest. Conversely, 
the global comprehensive approach, used in this analysis, 
includes all the expenditures incurred by a population 
with a particular disease.13 These expenditures are not 
necessarily related to the disease of interest; for instance, 
expenditures related to orthopaedics surgery or cancer 
treatment incurred by a patient with AF will count towards 
the global comprehensive cost of AF.
DAtA
Data were obtained from the Information Services Divi-
sion (ISD) of NHS Scotland as part of a wider project 
that used routinely collected data to evaluate clinical 
effectiveness and cost- effectiveness of direct oral antico-
agulants in the prevention of stroke in the AF popula-
tion. Inpatient records for patients with a diagnosis of AF 
or atrial flutter between 1997 and 2015 were extracted 
from the General Acute Inpatient and Day Case Scottish 
Morbidity Records 01 (SMR01). These records contain 
all general acute admissions, categorised as inpatients 
or day cases, discharged from non- obstetric and non- 
psychiatric specialties.14 Incident AF events (ICD10 code 
I48) were identified using all six diagnostic positions in 
SMR01, with a look back period of 5 years to minimise 
double counting. After checking for data entry errors 
and removal of duplicate records, the final AF cohort 
consisting of 278 286 individuals hospitalised with a diag-
nosis of AF or atrial flutter was identified.
Individual- level data linkage was then carried out with 
outpatient clinic attendance (Outpatient Attendance 
Scottish Morbidity Records 00; SMR00), the prescribing 
information system (PIS), care home census and mortality 
records (National Records for Scotland, NRS). Records 
from SMR00 include information on new and follow- up 
outpatient appointments for any clinical specialty.15 The 
PIS database includes prescribing records for all medi-
cines and their associated costs, which are prescribed and 
dispensed by community pharmacies, dispensing doctors 
and a small number of specialist appliance suppliers.16 
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Table 2 Regression results: probability of healthcare resources utilisation and cost estimation
Covariates
Probability
(first modelling part)
Cost ratios
(second modelling part)
Coefficient (95% CI) SE Coefficient (95% CI) SE
Age group (years)
  0–49 Reference
  50–54 0.329 (0.260 to 0.398) 0.035 0.036 (−0.016 to 0.087) 0.026
  55–59 0.388 (0.326 to 0.450) 0.031 0.081 (0.036 to 0.127) 0.023
  60–64 0.464 (0.407 to 0.521) 0.029 0.124 (0.082 to 0.166) 0.021
  65–69 0.486 (0.432 to 0.540) 0.028 0.157 (0.116 to 0.198) 0.021
  70–74 0.479 (0.426 to 0.533) 0.027 0.213 (0.174 to 0.252) 0.020
  75–79 0.536 (0.482 to 0.590) 0.027 0.222 (0.183 to 0.260) 0.020
  80–84 0.431 (0.375 to 0.486) 0.028 0.286 (0.246 to 0.326) 0.020
  85–89 0.378 (0.318 to 0.437) 0.030 0.375 (0.332 to 0.417) 0.021
  90—max 0.150 (0.083 to 0.217) 0.034 0.516 (0.468 to 0.564) 0.025
Sex
  Male Reference
  Female 0.045 (0.028 to 0.062) 0.009 0.054 (0.044 to 0.064) 0.005
Date of admission 0.169 (0.167 to 0.171) 0.001 −0.024 (−0.025 to −0.023) 0.001
SIMD quintile
  1 Reference
  2 0.027 (−0.018 to 0.071) 0.023 −0.055 (−0.080 to −0.031) 0.012
  3 −0.041 (−0.086 to 0.003) 0.023 −0.080 (−0.106 to −0.054) 0.013
  4 −0.046 (−0.091 to −0.002) 0.023 −0.116 (−0.141 to −0.090) 0.013
  5 −0.072 (−0.117 to −0.027) 0.023 −0.147 (−0.172 to −0.122) 0.013
Geography
  Large urban Reference
  Other urban −0.130 (−0.156 to −0.105) 0.013 −0.023 (−0.037 to −0.009) 0.007
  Accessible small towns −0.153 (−0.187 to −0.119) 0.017 −0.041 (−0.060 to −0.022) 0.010
  Accessible rural −0.197 (−0.230 to −0.165) 0.016 −0.043 (−0.062 to −0.024) 0.010
  Remote small towns −0.145 (−0.197 to −0.093) 0.027 0.009 (−0.023 to 0.041) 0.016
  Remote rural −0.288 (−0.335 to −0.241) 0.024 −0.036 (−0.065 to −0.007) 0.015
  Very remote small towns −0.380 (−0.459 to −0.300) 0.041 −0.057 (−0.107 to −0.006) 0.026
  Very remote rural −0.346 (−0.407 to −0.284) 0.031 −0.061 (−0.102 to −0.020) 0.021
Health boards
  Great Glasgow and Clyde Reference
  Lothian −0.044 (−0.075 to −0.014) 0.016 −0.033 (−0.049 to −0.017) 0.008
  Lanarkshire −0.005 (−0.038 to 0.029) 0.017 −0.063 (−0.081 to −0.045) 0.009
  Ayrshire and Arran −0.358 (−0.394 to −0.321) 0.019 −0.046 (−0.068 to −0.024) 0.011
  Grampian 0.017 (−0.019 to 0.054) 0.019 −0.059 (−0.078 to −0.039) 0.010
  Tayside −0.402 (−0.436 to −0.368) 0.018 −0.083 (−0.103 to −0.062) 0.010
  Fife −0.059 (−0.101 to −0.017) 0.022 −0.009 (−0.033 to 0.016) 0.012
  Highland −0.175 (−0.225 to −0.124) 0.026 −0.046 (−0.077 to −0.015) 0.016
  Forth Valley −0.477 (−0.518 to −0.436) 0.021 −0.109 (−0.135 to −0.082) 0.013
  Dumfries and Galloway −0.303 (−0.352 to −0.253) 0.025 −0.134 (−0.164 to −0.104) 0.015
  Borders −0.501 (−0.554 to −0.449) 0.027 −0.086 (−0.120 to −0.052) 0.017
  Western Isles −1.072 (−1.171 to −0.974) 0.050 0.457 (0.381 to 0.533) 0.039
  Orkney −0.362 (−0.492 to −0.232) 0.066 −0.029 (−0.117 to 0.059) 0.045
  Shetland −0.495 (−0.622 to −0.368) 0.065 −0.076 (−0.171 to 0.018) 0.048
Continued
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Covariates
Probability
(first modelling part)
Cost ratios
(second modelling part)
Coefficient (95% CI) SE Coefficient (95% CI) SE
Mortality within 5 years
  Alive Reference
  Dead 0.418 (0.376 to 0.461) 0.022 0.652 (0.630 to 0.674) 0.011
Comorbidity
  No comorbidities Reference
  1 comorbidity 0.666 (0.567 to 0.766) 0.051 0.374 (0.299 to 0.450) 0.038
  >1 comorbidities 1.205 (1.021 to 1.390) 0.094 0.990 (0.910 to 1.070) 0.041
SIMD, Scottish Index of Multiple Deprivation.
Table 2 Continued
The quality of PIS data is guaranteed by an electronic 
data capture, and it passes several stages of quality control 
before and after data are submitted.17 The care home 
census combines the former Residential Care Home 
Census (run by the Scottish Government) and the Private 
Nursing Homes Census (run by ISD Scotland). Items 
reported in the care home census include discharge dates 
to care home residency such as NHS and private nursing 
homes, as well as an indication on whether nursing care 
is required.16
Patients were followed up for 5 years following inci-
dent AF event in terms of their healthcare resource use, 
care home admissions and mortality. Since AF is often a 
precursor of stroke and cardiovascular conditions, an esti-
mation of costs for a period of 5 years post AF event would 
allow us to fully capture costs associated with a patient 
with AF.
COStIng
Inpatient care costs were obtained from the latest 
(2013/2014) Scottish National Tariff (SNT), a list of stan-
dard average prices based on Healthcare Resource Groups 
(HRGs).17 18 The SNT uses HRG4 for grouping clinically 
similar treatments that use similar levels of healthcare 
resources. After defining a total cost per episode, the total 
cost for a continuous inpatient stay (CIS) was calculated.
A CIS describes the entire duration of an inpatient stay 
from the date of admission to the date of discharge and 
can consist of several episodes in different specialties. 
Since the SNT is based on spells of care (inpatient stay 
within the same specialty) rather than individual inpa-
tient episodes or a CIS, a CIS was partitioned into spells 
when a change in specialty occurred.17 If within a CIS, 
two or more episodes were in the same specialty, only 
the highest incurred cost was taken into account, and 
the remaining episodes were replaced with a zero cost. 
Outpatient costs were obtained by assigning outpatient 
specialty costs to outpatient attendances.17 Unit costs 
were specific to whether the outpatient attendance took 
place at a consultant- led or nurse- led clinic.15
The cost of each prescription dispensed per patient was 
obtained from PIS.19 First, the price per unit was obtained 
by dividing the item price by the pack size. Second, the 
total number of items dispensed was obtained by multi-
plying the number of items dispensed by the number of 
instalments. Care home costs, obtained from the care 
home census, were based on length of stay or residency. 
Care home residency was established from care home 
census records, reporting admission to a care home- like 
structure.16 An average of care home charges for long stay 
residents was calculated using information on whether 
nursing care was provided or not. The average weekly 
care home charge was expressed per day, so that only 
the effective days spent in a care home were costed. The 
tariffs used for costing account for inflation, therefore 
further cost adjustment was not needed.
eCOnOMetrIC MODel
Healthcare expenditure data are typically characterised by 
(1) a significant proportion of zero- cost observations for 
individuals who have not used any healthcare resources 
in a given time period, and (2) a skewed distribution for 
positive costs. A two- part model was used.20 21
In the first part of the model, the probability of using 
a healthcare service in a given time period was estimated 
using a probit model (online supplementary equation I). 
The same explanatory variables were used in the second 
part of the model, with a gamma distribution and log link, 
estimating costs conditional on having incurred positive 
costs (online supplementary equation II). Mean costs per 
patient per year following their incident AF event were 
calculated by multiplying first and second modelling 
parts (online supplementary equation III).
In order to account for the skewed nature of cost data, 
generalised linear models (GLMs) were used. These 
were compared against ordinary least squares regression 
(OLS) and log- transformed OLS by means of the Akaike 
information criterion (AIC), which measures goodness of 
fit. When comparing the different models, GLM reported 
the lowest AIC, indicating the best fit for the given set of 
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Table 3 Regression results: probability of healthcare resources utilisation and cost estimation (alive at the end of the 5- year 
follow- up period)
Covariates
Probability
(first modelling part)
Cost ratios
(second modelling part)
Coefficient (95% CI) SE Coefficient (95% CI) SE
Age group (years)
  0–49 Reference
  50–54 0.352 (0.282 to 0.422) 0.036 0.067 (0.013 to 0.120) 0.027
  55–59 0.424 (0.361 to 0.488) 0.032 0.148 (0.098 to 0.199) 0.026
  60–64 0.528 (0.470 to 0.586) 0.030 0.218 (0.174 to 0.263) 0.023
  65–69 0.571 (0.516 to 0.627) 0.028 0.292 (0.248 to 0.336) 0.022
  70–74 0.603 (0.549 to 0.658) 0.028 0.412 (0.371 to 0.454) 0.021
  75–79 0.684 (0.630 to 0.739) 0.028 0.484 (0.443 to 0.525) 0.021
  80–84 0.572 (0.516 to 0.628) 0.028 0.615 (0.572 to 0.659) 0.022
  85–89 0.496 (0.435 to 0.557) 0.031 0.805 (0.756 to 0.854) 0.025
  90—max 0.206 (0.134 to 0.279) 0.037 1.044 (0.981 to 1.106) 0.032
Sex
  Male Reference
  Female 0.067 (0.048 to 0.086) 0.010 0.050 (0.037 to 0.063) 0.007
Date of admission 0.171 (0.170 to 0.173) 0.001 −0.059 (−0.060 to −0.057) 0.001
SIMD quintile
  1 Reference
  2 0.021 (−0.009 to 0.050) 0.015 −0.052 (−0.071 to −0.033) 0.010
  3 −0.023 (−0.054 to 0.008) 0.016 −0.081 (−0.101 to −0.060) 0.011
  4 −0.045 (−0.077 to −0.014) 0.016 −0.117 (−0.138 to −0.096) 0.011
  5 −0.051 (−0.083 to −0.020) 0.016 −0.160 (−0.181 to −0.139) 0.011
Geography
  Large urban Reference
  Other urban −0.140 (−0.169 to −0.112) 0.014 −0.030 (−0.049 to −0.012) 0.010
  Accessible small towns −0.172 (−0.210 to −0.134) 0.019 −0.052 (−0.077 to −0.026) 0.013
  Accessible rural −0.217 (−0.253 to −0.181) 0.018 −0.061 (−0.086 to −0.037) 0.013
  Remote small towns −0.145 (−0.203 to −0.087) 0.030 −0.007 (−0.048 to 0.035) 0.021
  Remote rural −0.319 (−0.371 to −0.268) 0.026 −0.064 (−0.101 to −0.027) 0.019
  Very remote small towns −0.404 (−0.491 to −0.318) 0.044 −0.098 (−0.161 to −0.036) 0.032
  Very remote rural −0.360 (−0.428 to −0.293) 0.034 −0.087 (−0.138 to −0.035) 0.026
Health boards
  Great Glasgow and Clyde Reference
  Lothian −0.055 (−0.090 to −0.020) 0.018 −0.051 (−0.072 to −0.030) 0.011
  Lanarkshire 0.003 (−0.034 to 0.040) 0.019 −0.072 (−0.095 to −0.048) 0.012
  Ayrshire and Arran −0.396 (−0.436 to −0.355) 0.021 −0.064 (−0.093 to −0.035) 0.015
  Grampian 0.029 (-0.013 to 0.070) 0.021 −0.051 (−0.077 to −0.026) 0.013
  Tayside −0.453 (−0.491 to −0.415) 0.019 −0.094 (−0.120 to −0.067) 0.014
  Fife −0.087 (−0.134 to −0.040) 0.024 −0.024 (−0.057 to 0.008) 0.017
  Highland −0.191 (−0.247 to −0.135) 0.029 −0.037 (−0.075 to 0.001) 0.020
  Forth Valley −0.520 (−0.566 to −0.474) 0.023 −0.108 (−0.141 to −0.074) 0.017
  Dumfries and Galloway −0.314 (−0.369 to −0.259) 0.028 −0.166 (−0.206 to −0.127) 0.020
  Borders −0.547 (−0.605 to −0.489) 0.030 −0.099 (−0.144 to −0.054) 0.023
  Western Isles −1.164 (−1.264 to −1.063) 0.051 0.139 (0.057 to 0.221) 0.042
  Orkney −0.394 (−0.535 to −0.252) 0.072 0.002 (−0.114 to 0.117) 0.059
  Shetland −0.605 (−0.740 to −0.470) 0.069 −0.044 (−0.172 to 0.085) 0.066
Continued
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Covariates
Probability
(first modelling part)
Cost ratios
(second modelling part)
Coefficient (95% CI) SE Coefficient (95% CI) SE
Comorbidity
  No comorbidities Reference
  1 comorbidity 0.705 (0.602 to 0.808) 0.052 0.432 (0.352 to 0.513) 0.041
  >1 comorbidities 1.165 (0.974 to 1.357) 0.098 1.133 (1.041 to 1.226) 0.047
SIMD, Scottish Index of Multiple Deprivation.
Table 3 Continued
data. A user- written STATA program ‘ glmdiagnostic. do’,20 
performing four different tests simultaneously, was used 
to identify the most appropriate distributional family and 
link function.
econometric model covariates
The two- part model adjusted for age, sex, year of inpa-
tient admission, socioeconomic status, urban–rural classi-
fication, health board, comorbidities and mortality. These 
covariates are considered to be the main confounders that 
have an effect on costs incurred by an AF population. We 
controlled for age because AF and associated comorbidi-
ties are age- related conditions and may have an impact on 
the overall costs. We also assumed costs to vary between 
men and women, in particular those for care home resi-
dency. Variation in healthcare utilisation and associated 
costs and care home residency by socioeconomic status is 
controlled for using the Scottish Index of Multiple Depri-
vation (SIMD).
The SIMD reflects areas of multiple deprivation ranked 
from the most to the least deprived and expressed as 
quintiles where the most and the least deprived areas 
are represented by 1 and 5, respectively.22 In Scotland, 
there are 14 regional health boards responsible for the 
provision of healthcare.23 Hence, potential differences in 
healthcare utilisation and prescribing costs may reflect 
variation in clinical practice and prescribing behaviour 
rather than the ability of patients to access care. Patients 
living in urban areas may have easier access to care 
compared with patients living in more remote areas, 
which is controlled for including the eightfold classifica-
tion measuring rurality.24
Patients with one or more comorbidities are expected 
to incur significantly higher costs than those with none. 
We accounted for this by including the Charlson Comor-
bidity Index, where 1 indicates the absence of comorbidi-
ties, 2 the presence of only a single comorbidity and 3 the 
presence of more than one comorbidity.25 Two interac-
tion terms between age and comorbidities, and mortality 
and SIMD were included in the econometric model. Intu-
itively, a relationship of direct proportionality between 
age and comorbidities suggests that the level of comor-
bidities increases as patients get older. Similarly, the socio-
economic status may significantly influence the rate of 
socioeconomic inequalities in mortality.26
SenSItIvIty AnAlySeS
In order to ascertain whether mortality had an impact 
on overall AF- related healthcare costs, average annual 
cost per patient by age and for each health or care home 
sector was estimated for patients who were alive and those 
who were dead at the end of the 5- year follow- up period. 
The two econometric models (Equation IV and V, please 
see online online supplementary equation IV and V) 
followed the same structure of the model described in the 
previous section and used for the main analysis; however, 
those models were not adjusted for mortality.
Patients and public involvement
There was no patients or public involvement.
reSultS
Cohort characteristics
Of the 278 286 patients with AF with a mean age of 74 
years (SD 12.5), the majority were identified in the two 
largest urban health board areas (Greater Glasgow and 
Clyde and Lothian), accounting for 22.2% and 14.8%, 
respectively. This is also reflected in our categorisation of 
geographical areas, where large urban represented 38.4% 
and other urban areas represented 29.7% of the total 
AF cohort. Greater proportion of patients live in areas 
belonging to the most deprived quintile compared with 
those living in the least deprived areas—SIMD quintile 1 
and quintile 5 representing 22.5% and 16.6% of the AF 
cohort, respectively (table 1).
econometric modelling results
Regression results for both modelling parts are presented 
in table 2. Overall, an inversely U- shaped association 
between age and the likelihood of utilising any health or 
social care services was observed—a gradual increment 
in the likelihood in resource use with advancing age up 
to 80 years, when compared with the reference group 
(0–49 years), while patients 80 years or older showing 
a decreased probability of utilising healthcare services. 
However, this association was not observed in the second 
modelling part model, estimating costs conditional on 
having incurred positive costs, where a statistically signifi-
cant gradient between age and costs indicated increasing 
costs as the cohort ages.
 o
n
 M
arch 31, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028575 on 18 March 2020. Downloaded from 
7Ciminata G, et al. BMJ Open 2020;10:e028575. doi:10.1136/bmjopen-2018-028575
Open access
Table 4 Regression results: probability of healthcare resources utilisation and cost estimation (dead at the end of the 5- year 
follow- up period)
Covariates
Probability
(first modelling part)
Cost ratios
(second modelling part)
Coefficient (95% CI) SE Coefficient (95% CI) SE
Age group (years)
  0–49 Reference
  50–54 0.150 (−0.125 to 0.426) 0.141 −0.112 (−0.405 to 0.180) 0.149
  55–59 0.134 (−0.098 to 0.366) 0.118 −0.093 (−0.334 to 0.147) 0.123
  60–64 0.129 (−0.080 to 0.338) 0.107 0.000 (−0.208 to 0.209) 0.106
  65–69 0.129 (−0.067 to 0.326) 0.101 −0.011 (−0.212 to 0.189) 0.102
  70–74 0.107 (−0.084 to 0.298) 0.097 0.016 (−0.180 to 0.213) 0.100
  75–79 0.128 (−0.059 to 0.315) 0.095 −0.005 (−0.198 to 0.189) 0.099
  80–84 0.132 (−0.053 to 0.318) 0.095 0.056 (−0.136 to 0.247) 0.098
  85–89 −0.048 (−0.233 to 0.137) 0.094 0.066 (−0.126 to 0.257) 0.098
  90—max −0.518 (−0.702 to −0.333) 0.094 0.097 (−0.095 to 0.290) 0.098
Sex
  Male Reference
  Female 0.048 (0.033 to 0.063) 0.008 0.028 (0.014 to 0.043) 0.007
Date of admission −0.040 (−0.042 to −0.039) 0.001 0.004 (0.002 to 0.005) 0.001
SIMD quintile
  1 Reference
  2 0.033 (0.011 to 0.055) 0.011 0.015 (−0.005 to 0.036) 0.011
  3 0.058 (0.034 to 0.082) 0.012 −0.008 (−0.030 to 0.015) 0.012
  4 0.065 (0.039 to 0.090) 0.013 −0.017 (−0.041 to 0.007) 0.012
  5 0.113 (0.088 to 0.138) 0.013 −0.024 (−0.049 to 0.000) 0.012
Geography
  Large urban Reference
  Other urban −0.010 (−0.032 to 0.012) 0.011 −0.033 (−0.054 to −0.012) 0.011
  Accessible small towns −0.006 (−0.036 to 0.025) 0.015 −0.049 (−0.077 to −0.021) 0.014
  Accessible rural −0.031 (−0.060 to −0.001) 0.015 −0.036 (−0.064 to −0.008) 0.014
  Remote small towns −0.054 (−0.102 to −0.005) 0.025 0.003 (−0.042 to 0.049) 0.023
  Remote rural −0.038 (−0.084 to 0.009) 0.024 −0.012 (−0.057 to 0.034) 0.023
  Very remote small towns −0.065 (−0.147 to 0.017) 0.042 0.036 (−0.052 to 0.123) 0.045
  Very remote rural 0.014 (−0.051 to 0.078) 0.033 −0.002 (−0.068 to 0.065) 0.034
Health boards
  Great Glasgow and Clyde Reference
  Lothian 0.029 (0.004 to 0.055) 0.013 0.029 (0.006 to 0.053) 0.012
  Lanarkshire −0.052 (−0.080 to −0.023) 0.014 −0.034 (−0.061 to −0.008) 0.013
  Ayrshire and Arran −0.122 (−0.155 to −0.089) 0.017 0.011 (−0.020 to 0.042) 0.016
  Grampian 0.075 (0.044 to 0.106) 0.016 −0.057 (−0.086 to −0.028) 0.015
  Tayside −0.024 (−0.056 to 0.007) 0.016 −0.061 (−0.089 to −0.033) 0.014
  Fife −0.028 (−0.064 to 0.008) 0.018 0.047 (0.012 to 0.082) 0.018
  Highland 0.034 (−0.015 to 0.084) 0.025 −0.065 (−0.117 to −0.013) 0.027
  Forth Valley −0.060 (−0.099 to −0.021) 0.020 −0.123 (−0.161 to −0.085) 0.019
  Dumfries and Galloway −0.027 (−0.074 to 0.020) 0.024 −0.014 (−0.058 to 0.029) 0.022
  Borders −0.058 (−0.112 to −0.005) 0.027 −0.023 (−0.074 to 0.029) 0.026
Continued
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Covariates
Probability
(first modelling part)
Cost ratios
(second modelling part)
Coefficient (95% CI) SE Coefficient (95% CI) SE
  Western Isles −0.033 (−1.168 to 1.102) 0.579 0.305 (−0.165 to 0.775) 0.240
  Orkney 0.191 (0.055 to 0.327) 0.069 −0.180 (−0.317 to −0.042) 0.070
  Shetland −0.031 (−0.170 to 0.108) 0.071 −0.187 (−0.323 to −0.052) 0.069
Comorbidity
  No comorbidities Reference
  1 comorbidity −0.176 (−0.449 to 0.097) 0.139 0.147 (−0.127 to 0.422) 0.140
  >1 comorbidities −0.256 (−0.491 to −0.021) 0.120 0.626 (0.401 to 0.851) 0.115
SIMD, Scottish Index of Multiple Deprivation.
Table 4 Continued
Table 5 Average annual costs per patient hospitalised with 
AF by sex
Sex
Cost estimates
Mean total cost (%) 95% CI
Male
  Inpatient 2935 (79.99) (2915 to 2955)
  Outpatient 31 (8.46) (308 to 313)
  Care home 165 (4.50) (154 to 177)
  PIS 242 (6.60) (240 to 245)
  Total 3669 (3872 to 3927)
Female
  Inpatient 3022 (77.49) (3001 to 3042)
  Outpatient 310 (7.96) (308 to 313)
  Care home 268 (6.88) (255 to 281)
  PIS 259 (6.64) (256 to 262)
  Total 3968 (3872 to 3927)
PIS, prescribing information system.
The use of health or social care services and associated 
costs also increased significantly for patients living in the 
most deprived areas, when compared with patients living 
in areas with the lowest level of deprivation. The effect 
of socioeconomic status on healthcare utilisation was also 
measured for those who are alive at the end of the 5- year 
follow- up period through an interaction term between 
SIMD and mortality, but no statistically significant effect 
was found.
Full details of regression results for interaction terms 
are presented in the online supplementary table I.
For patients with comorbidities, the probabilities of util-
ising healthcare services were greater than the probability 
for those with no comorbidities. Although healthcare util-
isation increased with the number of comorbidities, the 
interaction term between age and comorbidities indicated 
that as patients get older, the use of healthcare services on 
average is lower for patients with one or more comorbid-
ities than those with none. The decrease in healthcare 
utilisation by age is more pronounced in patients with 
more comorbidities than in those with only one comor-
bidity. The difference in healthcare costs between comor-
bidity categories indicated that in the presence of one or 
more comorbidities, on average healthcare costs decrease 
as patients get older. Full details of regression results 
for patients who were alive and those who were dead at 
the end of the 5- year follow- up period are presented in 
tables 3 and 4, respectively, while regression results for 
interaction terms are presented in the online supplemen-
tary tables II and III.
COSt eStIMAteS
The estimated mean annual cost per AF patient was £3785 
(95% CI £3767 to £3804). The estimated total costs and 
distribution of costs according to sex are shown in table 5.
While there is little difference between the total 
costs and the distribution of costs for inpatient, outpa-
tient and prescription costs, the difference seems more 
pronounced when comparing the care home component 
of costs (5% of total costs among male vs 7% of total costs 
among female).
The average annual cost per AF patient by age and for 
each health or care home sector is shown in figure 1. 
Considering the individual contribution of each cost 
component to the overall costs, inpatient cost was the 
main driver across all age groups. While inpatient cost 
contribution remained constant with an average contri-
bution of about 80% to the overall costs for patients aged 
between 0 and 84 years, it decreased for patients over 85 
years of age. Similar patterns were observed for outpa-
tient and prescribing costs. On the contrary, the contri-
bution of care home costs to the overall costs increased 
with age (0.5% for patients aged 0–49 years and approx-
imately 11% for patients who are 90 years or older). The 
contribution of each setting to the total health and care 
home costs by the number of existing comorbidities is 
illustrated in figure 2. While inpatient and total costs vary 
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Figure 1 Average annual costs per patient hospitalised with AF by sector. Cost components with CI are presented for each 
age group. AF, atrial fibrillation; PIS, prescribing information system.
Figure 2 Average cost per patient hospitalised with AF by Charlson Comorbidity Index. Cost components with CI are 
presented for each comorbidity category. AF, atrial fibrillation; PIS, prescribing information system.
considerably with the number of comorbidities, outpa-
tient and care home contributions remain fairly constant.
The estimated mean annual cost per AF patient alive 
at the end of the 5- year follow- up period was £3047 (95% 
CI £3027 to £3067). The average annual cost per AF 
patient by age and for each health or care home sector 
is presented in the online supplementary figure I. For 
these patients, inpatient cost was the main driver across 
all age groups; a gradient between age and costs indicated 
increasing costs as the cohort ages. Similar patterns were 
observed for care home costs. On the contrary, outpatient 
and prescribing costs remained constant up to 74 years, 
but decreased slightly for older patients.
The estimated mean annual cost per AF patient who 
died during the 5- year follow- up period was £2304 (95% 
CI £2284 to £2324) (online supplementary figure II). For 
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these patients, inpatient cost was the main driver across 
all age groups; a gradient between age and costs indicated 
decreasing costs as the cohort ages. This was also observed 
for outpatient and prescribing costs; but care home costs 
on average increased across age groups.
DISCuSSIOn
A greater proportion of patients with AF were found 
in areas with the highest index of deprivation. This, 
combined with the likelihood for people living in the 
most deprived quintile having longer inpatient stays due 
to a lack of support at home, may explain the difference in 
inpatient care utilisation between patients from the most 
and the least deprived areas, with associated costs being 
higher for the former group. As AF is more likely to affect 
the elderly, so that costs were expected to increase with 
age. As health deteriorates with age, older age groups are 
assumed to make greater use of healthcare services, and 
therefore incur higher costs than younger age groups. 
However, age was found to have a modest impact on 
overall healthcare costs, being fairly consistent across age 
groups. This finding is in line with existing evidence indi-
cating that healthcare expenditure depends not only on 
patients’ calendar age but is also significantly associated 
with remaining lifetime.27
Any observed correlation between healthcare expendi-
ture and age may therefore be attributable to the fact that 
the proportion of patients who are at the end of their lives 
is substantially greater in older rather than younger age 
groups.27 On the other hand, comorbidity had a consid-
erable effect on the overall costs, increasing significantly 
in patients with more than one comorbidity. However, 
the decrease in healthcare utilisation by age is more 
pronounced in patients with more comorbidities than in 
those with only one comorbidity.
Decreasing inpatient and outpatient costs for the oldest 
patients were offset by increasing care home costs, in 
particular for women. Indeed, the main cause for higher 
overall costs incurred by women is attributable to the 
higher likelihood for elderly women to reside in care 
homes.
Interestingly, care home contribution to the overall 
costs was noticeably lower for patients with multiple 
comorbidities than for those with none or one comor-
bidity. This may suggest that sicker patients are more 
likely to be in hospital than in a care home.
To date, only one single study published in 2004 has 
estimated the cost of AF in Scotland; the authors esti-
mated the cost of AF in 1995/1996 with the medicalised 
approach, and projected these to the year 2000.28 Previous 
work has focused on a 12- month follow- up, which seems 
limited in order to capture all healthcare resource util-
isation for patients with AF. Our study offers a longer 
follow- up and a contemporary estimate of healthcare 
costs related to AF including all relevant care settings. 
Our study offers a distinct advantage over previous work 
as costs, rather than being based on extrapolated rates 
using a prevalence- based approach,28 are estimated with 
an incidence- based method using patient- level morbidity 
records. Using an incidence- based approach to costing 
and a broad perspective to capture the majority of costs 
associated with AF, several routinely collected adminis-
trative datasets from Scotland were combined, including 
care home utilisation.
Existing studies, including ours, regardless of econo-
metric model choice and covariates used, show that costs 
due to inpatient admission are the main contributor to 
overall AF- related healthcare cost. This is a pertinent 
finding that may well support future policies on oppor-
tunistic screening in the population at risk of AF, and in 
particular in Scotland where one in three patients with 
AF are currently undiagnosed.29
The European AF management guidelines and the 
Scottish Cross- Party Group ‘Heart Disease and Stroke’ 
recently recommended that people who are 65 years or 
older and at risk of AF and associated comorbidities such 
as cardiovascular disease, diabetes or respiratory disease 
should be screened opportunistically in primary care, 
pharmacies or community settings.29 30 With rigorous 
screening and appropriate treatment, hospitalisations 
could be avoided and costs reduced.
Although we have captured most healthcare sectors and 
related costs, we were not able to obtain national data on 
primary care consultations, as these data are currently not 
routinely available for linkage in Scotland. Not capturing 
these data may lead to an underestimation of the size of 
the AF cohort and associated costs. However, the cost 
associated with primary care consultations is expected 
to have a limited impact on the overall total AF- related 
costs. Such underestimation could also result from AF 
going undiagnosed and clinical miscoding of morbidity 
records. Nevertheless, by using a cohort of patients hospi-
talised with AF, we were able to capture more severe cases 
of AF. Prescribing and care home data were only avail-
able respectively from 2009 to 2012, their contribution 
to overall AF- related costs might also be underestimated. 
Other limitations are inherent to the nature of adminis-
trative data, such as missing records or incomplete data.
Further, we acknowledge the issue concerning attrib-
uting AF- related costs to patients with a structural heart 
disease, as AF may manifest subsequently because of this. 
In our analysis, we identified about 14% of AF patients 
with a structural heart disease; these were patients with 
systolic dysfunction, valvular heart disease or heart valve 
replacement. However, from the hospital data, it was not 
possible to establish causation between structural heart 
disease and AF.
In addition, this is likely to have a marginal impact on 
our conclusions, as the global comprehensive approach 
used in this study include expenditures that are not 
necessarily related to AF.
We also acknowledge that specifying whether patients 
had received cardiovascular procedures (eg, cardiover-
sion, echocardiograms and angiograms) would improve 
the accuracy of our cost estimation, as it would indicate 
 o
n
 M
arch 31, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028575 on 18 March 2020. Downloaded from 
11Ciminata G, et al. BMJ Open 2020;10:e028575. doi:10.1136/bmjopen-2018-028575
Open access
whether costs should be attributable to AF or other forms 
of structural heart disease. However, this information is 
not currently available in our routinely collected data of 
hospital admissions.
Recognising these limitations, we were nevertheless 
able to harness high- quality patient- level linked data to 
identify a cohort of patients with AF and to estimate their 
associated healthcare utilisation and costs in Scotland.
The inclusion of all available cost components is crucial 
for establishing overall costs, as these often extend 
beyond hospitalisation. The study identifies hospitalisa-
tion as the main cost driver and suggests that the imple-
mentation of AF screening policies could substantially 
reduce AF- related healthcare costs. Most importantly, the 
study concludes that patient’s age has a limited impact on 
the overall AF- related cost and therefore may contribute 
much less to future growth of AF- related cost in an ever- 
ageing Scottish population.
Future work will be able to use Scottish Stroke Care 
Audit (SSCA) records, allowing for the identification of 
additional patients with AF ; these are patients hospital-
ised with a stroke, where AF has been recorded in audit 
data as an underlying comorbidity.
Being able to complement inpatient records with SSCA 
records will allow us to capture more patients with AF 
in Scotland. Moreover, future research may be able to 
include indirect costs associated with productivity loss 
by linking morbidity and prescribing data to national 
data from the Department for Work and Pensions, for 
instance.
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